Payment overview · 2025
General Payments
$1,185.94
43 reported records · 15 companies
Healthcare provider profile · identity verified
Sandy Chan
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · BROOKLYN, NY · NPI 1205366267
Verified facts
What the public records show
CMS Open Payments records show Sandy Chan received $1,185.94 in general payments during 2025 across 43 reported records.
ABBVIE INC. accounted for 19.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Linzess, Prolia, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Symbicort by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $229.24 | 19.3% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $210.65 | 17.8% | 10 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $159.11 | 13.4% | 3 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $142.63 | 12.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $84.11 | 7.1% | 4 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $61.63 | 5.2% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $60.41 | 5.1% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $54.40 | 4.6% | 2 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $40.17 | 3.4% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $32.19 | 2.7% | 2 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $27.90 | 2.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $22.40 | 1.9% | 1 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.19 | 1.9% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $21.02 | 1.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.89 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,185.94 | 43 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $159.11 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $151.03 | 7 | 2025 |
Source payment records
|
|||||
| Livdelzi Normalized: livdelzi |
Drug | Gilead Sciences, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $123.96 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $105.28 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $86.59 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $84.11 | 4 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $61.63 | 3 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $40.17 | 2 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $40.17 | 2 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $40.17 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $38.93 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $34.10 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $30.25 | 2 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $27.90 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $26.31 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $22.40 | 1 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $22.19 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $21.02 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20.69 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.89 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $15.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 165 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 74 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 40 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 141 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
74 | 22 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
105 | 39 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
40 | 30 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
165 | 56 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
55 | 36 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
141 | 42 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1200 | 546 |
| Losartan Potassium | Losartan Potassium | 802 | 357 |
| Amlodipine Besylate | Amlodipine Besylate | 614 | 269 |
| Montelukast Sodium | Montelukast Sodium | 374 | 154 |
| Tamsulosin Hcl | Tamsulosin Hcl | 342 | 148 |
| Vascepa | Icosapent Ethyl | 340 | 105 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 334 | 103 |
| Donepezil Hcl | Donepezil Hcl | 319 | 144 |
| Azelastine Hcl | Azelastine Hcl | 301 | 109 |
| Raloxifene Hcl | Raloxifene Hcl | 296 | 135 |
| Metformin Hcl | Metformin Hcl | 260 | 122 |
| Ammonium Lactate | Ammonium Lactate | 253 | 109 |
| Diclofenac Sodium | Diclofenac Sodium | 249 | 117 |
| Meloxicam | Meloxicam | 243 | 170 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 214 | 68 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 207 | 62 |
| Carvedilol | Carvedilol | 207 | 84 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 205 | 81 |
| Alendronate Sodium | Alendronate Sodium | 198 | 72 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 197 | 84 |
| Zolpidem Tartrate | Zolpidem Tartrate | 189 | 89 |
| Gabapentin | Gabapentin | 186 | 59 |
| Omeprazole | Omeprazole | 175 | 129 |
| Metoprolol Succinate | Metoprolol Succinate | 173 | 74 |
| Azithromycin | Azithromycin | 170 | 157 |
| Farxiga | Dapagliflozin Propanediol | 165 | 56 |
| Jardiance | Empagliflozin | 155 | 55 |
| Fluticasone Propionate | Fluticasone Propionate | 150 | 85 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 141 | 42 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 134 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 131 | 55 |
| Allopurinol | Allopurinol | 130 | 59 |
| Finasteride | Finasteride | 128 | 50 |
| Meclizine Hcl | Meclizine Hcl | 125 | 105 |
| Januvia | Sitagliptin Phosphate | 116 | 33 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 113 | 51 |
| Hydrocortisone | Hydrocortisone | 111 | 63 |
| Simvastatin | Simvastatin | 111 | 38 |
| Colchicine | Colchicine | 109 | 42 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 108 | 44 |
| Atenolol | Atenolol | 106 | 38 |
| Halobetasol Propionate | Halobetasol Propionate | 105 | 87 |
| Synthroid | Levothyroxine Sodium | 105 | 39 |
| Metformin Hcl Er | Metformin Hcl | 98 | 40 |
| Memantine Hcl | Memantine Hcl | 86 | 35 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 85 | 28 |
| Lisinopril | Lisinopril | 85 | 37 |
| Clobetasol Propionate | Clobetasol Propionate | 81 | 57 |
| Mirtazapine | Mirtazapine | 81 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 80 | 31 |
| Procto-Med Hc | Hydrocortisone | 77 | 25 |
| Levothyroxine Sodium | Levothyroxine Sodium | 75 | 30 |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 75 | 22 |
| Linzess | Linaclotide | 74 | 22 |
| Eliquis | Apixaban | 73 | 32 |
| Dicyclomine Hcl | Dicyclomine Hcl | 72 | 63 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 69 | 23 |
| Dutasteride | Dutasteride | 65 | 19 |
| Prednisone | Prednisone | 65 | 49 |
| Glipizide Er | Glipizide | 64 | 28 |
| Celecoxib | Celecoxib | 61 | 33 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 60 | 24 |
| Loperamide | Loperamide Hcl | 56 | 50 |
| Tradjenta | Linagliptin | 56 | 17 |
| Ibuprofen | Ibuprofen | 55 | 52 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 55 | 36 |
| Ketoconazole | Ketoconazole | 54 | 29 |
| Famotidine | Famotidine | 53 | 30 |
| Valsartan | Valsartan | 52 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 51 | 21 |
| Furosemide | Furosemide | 48 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 46 | 34 |
| Alcohol Pads | Alcohol Antiseptic Pads | 45 | 14 |
| Fluocinonide | Fluocinonide | 45 | 26 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 45 | 21 |
| Bepotastine Besilate | Bepotastine Besilate | 44 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 42 | 23 |
| Vemlidy | Tenofovir Alafenamide | 42 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 41 | suppressed |
| Prolia | Denosumab | 40 | 30 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 39 | 20 |
| Xarelto | Rivaroxaban | 38 | 14 |
| Amoxicillin | Amoxicillin | 37 | 36 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 36 | 19 |
| Edarbi | Azilsartan Medoxomil | 36 | 12 |
| Mupirocin | Mupirocin | 36 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 36 | 20 |
| Rivastigmine | Rivastigmine | 36 | 13 |
| Trazodone Hcl | Trazodone Hcl | 36 | 17 |
| Glipizide | Glipizide | 35 | 15 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 34 | 15 |
| Mometasone Furoate | Mometasone Furoate | 33 | 24 |
| Telmisartan | Telmisartan | 33 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 27 |
| Fenofibrate | Fenofibrate,micronized | 32 | 19 |
| Potassium Chloride | Potassium Chloride | 32 | 19 |
| Ventolin Hfa | Albuterol Sulfate | 32 | 11 |
| Nifedipine Er | Nifedipine | 31 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 30 | 13 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | 14 |
| Lidocaine | Lidocaine | 29 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Febuxostat | Febuxostat | 28 | suppressed |
| Rybelsus | Semaglutide | 28 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 27 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | 12 |
| Folic Acid | Folic Acid | 26 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 25 | 14 |
| Diclofenac Epolamine | Diclofenac Epolamine | 23 | 20 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 23 | 14 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 22 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 22 | suppressed |
| Methimazole | Methimazole | 22 | 11 |
| Ozempic | Semaglutide | 22 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Acarbose | Acarbose | 20 | suppressed |
| Naproxen | Naproxen | 20 | 16 |
| Ranolazine Er | Ranolazine | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Ciclopirox | Ciclopirox | 19 | suppressed |
| Cilostazol | Cilostazol | 19 | suppressed |
| Clotrimazole | Clotrimazole | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 18 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 17 |
| Scopolamine | Scopolamine | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 16 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 16 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 16 |
| Dapagliflozin | Dapagliflozin Propanediol | 16 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Timolol Maleate | Timolol Maleate | 16 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 15 | 13 |
| Creon | Lipase/Protease/Amylase | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Alprazolam | Alprazolam | 13 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Alphagan P | Brimonidine Tartrate | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | 12 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 12 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,185.94 · 43 records | ABBVIE INC. | AIRSUPRA, BREZTRI, CAPLYTA, CAPVAXIVE, COLLAGENASE SANTYL, CREON, Cologuard Collection Kit, EVENITY, FARXIGA, GLYCATE, LINZESS, Livdelzi, PROLIA, PYRUKYND, RELTONE 200 MG, RELTONE 400 MG, REPATHA, REXULTI, REZDIFFRA, SKYRIZI, TRELEGY ELLIPTA, Vest Therapy Und | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error